Zhuhai Kerui Biotechnology (revision 29)
Old revision·20:14, 11 Oct 2025·CounterfeitCato
| Zhuhai Kerui Biotechnology Co., Ltd.Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | Zhuhai Kerui Biotechnology Co., Ltd. |
| Trading name | KP |
| Other designations | KP Biotech, Zhuhai Kerui Biotechnology |
| Identity | |
| Founded | 2016 |
| Headquarters | Zhuhai, China |
| Industry | Research-compound supply |
| Shop domain | Visit KP |
| Products and documentation | |
| Product scope | peptides, SARMs, injectable oils and raw materials |
| Catalogue size | 350+ listings (self-reported) |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| PeptidePedia reception tally | |
| Submissions | 791 to July 2026 |
| Evidence quality | Weak — self-selected, self-reported |
| Organisation infobox · conventions | |
Zhuhai Kerui Biotechnology Co., Ltd. (trading as KP; keruipeptides.com) is a research-peptide supplier trading as KP from Zhuhai, Guangdong, China, incorporated in 2016, supplying research peptides and related materials with batch documentation and tracked international shipping.[1][2]
The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]Incorporated in 2016 in Zhuhai, on the western side of the Pearl River Delta adjacent to Macau, the organisation operates from one of China's more established special economic zones.[1] The location has a practical consequence visible in purchaser reports: outbound shipments frequently route through Hong Kong or Macau, and reported transit times to Europe and North America have been among the shorter in this set.[5]
The documentary base is the registry record, the organisation's own material and purchaser reports. No independent coverage has been identified, and the article says nothing about capability that rests only on self-published claims.
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Reports describe lyophilised material in crimped glass vials with a batch certificate reporting purity, appearance and, in most of the submitted set, a water content.[5] Insulated packaging with a gel pack is described for the incretin lines.
One documentation practice recorded across several reports is worth noting: certificates in this set have named the analytical method and column, which is uncommon. A purity figure with a stated method is more useful than one without, because area percent depends on the separation that produced it.[6]
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Incretin analogues | Semaglutide, tirzepatide, retatrutide | Certificate with method, purity, water |
| Research peptides | Repair and secretagogue peptides | Certificate with method |
| SARMs | Bulk | Certificate, purity |
| Raw materials and oils | Bulk | Certificate, limited detail |
Method disclosure on the peptide lines is the distinguishing documentation feature. It does not make the figure correct; it makes it checkable, which is a different and more useful property.[6]
Independent testing record
[edit]Submitted reports on KP material to July 2026 are concentrated on the incretin analogues. Reported area percent figures have clustered in the high nineties, and because the accompanying certificates named the method, several purchasers were able to run a comparable separation rather than a merely similar one.[5]
Where method conditions match, agreement between an independent report and a certificate is a meaningfully stronger observation than where they do not — much of the routine disagreement between two purity figures is attributable to different columns and integration parameters rather than to different material.[6]
Reception
[edit]The PeptidePedia tally records 791 self-reported submissions to July 2026. Recurring positive themes are certificate detail, method disclosure and transit time; recurring complaints concern documentation on the bulk lines.[4] Self-selected; reception rather than quality.[4]
See also
- Certificate of analysis
- Third-party testing
- Area percent purity
- Peptide content
- Research use only
- Peptide supply chain
References
- ^ a b National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ a b c PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ a b c Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
- ^ a b c United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.